Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of intravenous ulimorelin versus metoclopramide in enteral feeding intolerance
2016-000723-94Phase 2Completed
- Sponsor
- Lyric Pharmaceuticals
- Start
- May 2016
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ulimorelin in enteral feeding intolerance (EFI) (2 arms), sponsored by Lyric Pharmaceuticals. Primary endpoint: Primary efficacy endpoint. Started May 2016; status: completed.
02
Drugs
ulimorelin
03
Conditions
enteral feeding intolerance (EFI)
Beyond the preview
Go deeper on 2016-000723-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000723-94.